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Background: Previous studies have suggested that pre-stroke treatment with low-dose aspirin (A) could reduce the
severity of acute ischaemic stroke, but less is known on the effect of pre-stroke treatment with a combination of
aspirin and dipyridamole (A + D) and post-stroke effects of these drugs. The aim of the present study was to
evaluate the effect of this drug combination on acute and long-term prognosis of ischaemic stroke.
Methods: Patients without atrial fibrillation admitted to the stroke unit with acute ischaemic stroke (n = 554) or TIA
(n = 108) were studied during acute hospital care and up to 12 months after discharge from hospital.
Results: Prior to acute stroke 62 patients were treated with A + D while 247 patients were treated with A only. No
beneficial effects of the combination A + D compared to A only were noted on stroke severity and/or acute
in-hospital mortality. However, survival analysis by Cox-proportional hazard model demonstrated lower 12-months
all-cause mortality in patients discharged with A + D (n = 275) compared with patients on A only (HR, 0.52; CI, 0.32-
0.86; p = 0.011; n = 262) after adjusting for age, baseline NIHSS, previous stroke, previous myocardial infarction and
type 2 diabetes. We also noted a tendency towards lower all-cause mortality at 3 months with use of A + D, but
this was not statistically significant (p = 0.12).
Conclusions: Pre-stroke treatment with a combination of low-dose A + D does not reduce the severity of acute stroke,
nor does it reduce the acute in-hospital mortality. However, treatment with A + D at discharge from hospital is seemingly
associated with lower long-term mortality compared with A only, contrary to the results from previous randomised
studies. However, our results must be interpreted with extreme caution considering the non-randomised study design.
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Several reports have suggested that patients suffering an
acute ischaemic stroke while treated with aspirin have less
severe strokes than those who are not on aspirin [1-3].
However, other studies have failed to demonstrate such an
effect [4-6]. It has been hypothesized that antiplatelet
drugs, such as aspirin, may limit the size and extent of
thrombosis and subsequent emboli and thereby reduce
stroke volume [1].* Correspondence: bjorn.andersson@vgregion.se
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distribution, and reproduction in any mediumDipyridamole (D) is clinically distributed in extended-
release form and is primarily recognized as an antithrom-
botic agent with antiplatelet properties. It has been sug-
gested to reduce the inflammatory process during the sub-
acute stroke stages which may be beneficial in the ischae-
mic stroke setting [7]. This drug has, in combination with
aspirin, been shown to improve outcome, reduce stroke
recurrence and vascular death in patients with previous
stroke [8-13]. There is, however, a paucity of data on the
effect of pre-stroke treatment with A + D and the effects
of such a combination on early post-stroke outcome.
Therefore, the aim of the present study was to exam-
ine the effect of pre-stroke treatment with A + D vs. Antral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Baseline demography, risk factors and NIHSS in
patients admitted for acute stroke/TIA (n = 662)
Variables % or Mean = ±SD
Age(years) 77 ± 9
Male(%) 48.2
Female(%) 51.8











NIHSS: National Institute of Health Stroke Scale, SD: Standard Deviation.
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as to examine the post-stroke effects of these drugs on
all-cause mortality and cardiovascular morbidity. The
study results are presented in the current paper.
Methods
All acute ischaemic stroke/TIA patients within preced-
ing 7days were consecutively recruited from the Stroke
Unit, Department of Internal Medicine, Sahlgrenska
University Hospital, from February 15 – May 31, 2009.
No patients were included December 31, 2006 - Septem-
ber 3, 2007, due to data management. Patients with
atrial fibrillation/flutter were excluded from the present
analysis since use of A + D is not recommended in
patients with atrial fibrillation. Stroke was defined
according to World Health Organization definition [14].
TIA was defined as a reversible episode of neurologic
deficit of ischaemic origin that resolved completely
within 24 hours. In all patients a cerebral computed
tomography (CT) scan was performed within 24 hours
of admission.
For those patients with ischaemic stroke, not already on
antiplatelet, treatment with antiplatelet was initiated after
the initial CT scan. A detailed medical and drug history
was obtained from each patient and next of kin from the
attending physician with specific standardized questions
regarding previous cardiovascular diseases. Medical
records were thoroughly examined. Since the aim of the
present study was to compare stroke outcome in patients
with low-dose A vs. A + D, patients on other antiplatelet
or anticoagulants were not included in this analysis.
On admission, the National Institute of Health Stroke
Scale (NIHSS) [15,16] was used to assess stroke severity.
All strokes were classified according to the TOAST cri-
teria [17]. Systolic and diastolic blood pressures were
measured in a supine position after 5 minutes rest at ad-
mittance, and on days 1, 2, 3, 7, and at discharge. Total
cholesterol, triglycerides, high-density lipoprotein chol-
esterol (HDL-C) and low-density lipoprotein cholesterol
(LDL-C) were measured by routine laboratory methods
within the first 24 hours after admittance.
Cardiovascular end-points (coronary heart disease,
congestive heart failure, and recurrent stroke/TIA) and
medication were documented upon pre-scheduled 3 and
12-month follow-up outpatient clinic visits. NIHSS and
Modified Rankin Scale (mRS) [18] were recorded at each
visit. The medical records of these patients who did not
show up at the scheduled visits was screened for cardio-
vascular endpoints. Recurrent stroke/TIA was defined as
a stroke/TIA > 30days after the index stroke/TIA.
Survival and functional outcome
Mortality data at 30 days, 3 and 12 months after index
stroke/TIA was obtained from ELVIS (Swedish PopulationRegistry). Data was, thus, extracted both from medical
records and from interviews with patients in the ward
during acute stroke and then at follow-up clinical visits.
For those patients who did not attend the outpatient clinic
visits, mRS was estimated by telephone interview with
patients, next of kin or staff at nursing homes [19].
The study was approved by the Ethics Committee of
The University of Göteborg. Written informed consent
for participation in the study was obtained from the
patients or their families. All patients were adults.Statistical analyses
The Mann–Whitney U test was used to compare the
mean values of continuous variables (NIHSS, mRS) by
treatment, while the chi-square test was used to com-
pare categorical variables. Survival by treatment group
was investigated by Cox proportional hazard regression
where age, NIHSS at admission, as well as pre-stroke
medical conditions (previous ischaemic stroke, previous
myocardial infarction and type 2 diabetes) were used as
covariates. Data are presented as hazard ratio (HR) with
95% confidence intervals (CI). P-values <0.05 were
regarded as statistically significant (2-sided tests). All
statistical analyses were performed by using SPSS,
version 19.0. (Chicago, Illinois, USA).Results
Altogether 662 patients with ischaemic stroke (n = 554)
or TIA (n = 108) were included in the study. Mean age
was 76.8 ± 8.6 (Mean ± SD) years.
Baseline demographics and risk factors are summar-
ized in Table 1.
Figure 1 Survival analysis. Cumulative survival in patients treated
with aspirin only or aspirin plus dipyridamole after initial acute
ischaemic stroke/TIA. P-value for differences in 1-year survival
between these two groups.
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shown in Table 2. The most frequent used doses were:
75mg aspirin daily and 200mg dipyridamole, twice daily.
Outcomes
Acute stroke severity, as measured by NIHSS, did not
differ between patients on A + D , patients on A only, or
patients with no antiplatelet treatment at all (not
shown). The total 30-day mortality was 5.1% and no sta-
tistically significant difference was noted between the
groups.
The cumulative all-cause mortality rates were 9.4%
and 13.8%, at 3months and 12-months, respectively. The
participation rate for 3 and 12-months follow-up clinic
visits were 75% and 70%, respectively.
Altogether 628 patients with ischaemic stroke or TIA
and without atrial fibrillation were discharged after
acute stroke. At discharge there was no difference in
systolic or diastolic blood pressure nor in total choles-
terol, LDL-C, or triglycerides between users of A + D
and users of aspirin only (not shown). HDL-C was
slightly lower in the A + D group (1.46mmol/L ± 0.5; vs.
1.51mmol/L ± 0.42; p = 0.03).
Survival
Survival analysis by Cox–proportional hazard model
demonstrated that 12-months all-cause mortality was
decreased in patients taking A + D compared with patients
on aspirin only (HR, 0.52; CI, 032–0.86; p = 0.01) (Figure 1),
after adjusting for age, NIHSS at admittance, previous
ischaemic stroke, previous myocardial infarction and type
2 diabetes. Age (HR, 1.07; CI, 1.01-1.13; p = 0.021), and
baseline NIHSS (HR, 1.08; CI, 1.02-1.14; p = 0.01), were
also independent predictors of 12-months mortality.
There was also a tendency to decreased mortality,
albeit not fully significant, in the A + D group in com-
parison with aspirin only group already after 3months
(p = 0.12). There was, however, neither difference in
functional outcome (mRS) at 3 and 12months, nor in
occurrence rate of cardiovascular events (non-fatal
myocardial infarction, stroke/TIA, ischemic heart dis-
ease or congestive heart failure) (Table 3).Table 2 Use of antithrombotic pre-stroke medication and
antithrombotic medication at discharge after acute
stroke/TIA
Drug Pre-stroke use Use at discharge
(n = 662 patients) (n = 628patients)
Aspirin + Dipyridamole 62 275
Aspirin only 247 262
Clopidogrel 11 28
Warfarin 10 38
No use of antithrombotic 332 25Discussion
Our study shows that pre-stroke treatment with A + D
does not reduce acute stroke severity in comparison with
aspirin only. However, at the end of the 12-months fol-
low-up period, patients on A + D had lower all-cause
mortality compared with patients on A only. There was
no difference in functional outcome and/or non-fatal
cardiovascular events between patients on A + D or A
only during follow-up.
In some previous studies [1-3], pre-stroke aspirin use
has been associated with milder clinical deficits at stroke
onset, but reduction in stroke severity may also differ by
stroke mechanisms [20].
Few and, partly inconclusive, data are available on the
effect of pre-stroke treatment with A + D on stroke
severity [10]. Theoretically, D is suggested to be neuro-
protective [7] and may reduce the inflammatory process.Table 3 Mortality at 3 and 12 months and cardiovascular
events in patients using aspirin + dipyridamole (A + D)
vs. use of aspirin only (A) after acute stroke/TIA (%)
3-mo 12-mo 3-mo CVD 12-mo CVD
Aspirin + Dipyridamole 1.1 5.7** 5.7 14.7
(n = 275)
Aspirin only 5.7 10.7 3.8 10.9
(n = 262)
** = P < 0.01 for comparison A + D vs.A only, : mortality, CVD: Cardiovascular
Disease (recurring stroke/TIA, non-fatal myocardial infarction, congestive heart
failure, ischemic heart disease), 3-mo: 3-months mortality; 12-mo: 12-months
mortality. Results are presented in percent(%).
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of aspirin might provide more efficient neuroprotection
[10].
However, our study, in agreement with recent data [10]
does not suggest that use of A + D before stroke onset
would lessen severity of acute stroke. In spite of this, any
conclusions must be drawn with caution since the number
of patients using A + D before stroke was considerably
smaller than the number of patients using aspirin only.
Our finding of reduced all-cause mortality in the A + D
group at 12months follow-up is somewhat puzzling. Previ-
ously two large, randomised, studies [8,9] have shown A +
D to be effective for secondary stroke prevention, but all-
cause mortality was not reduced. Furthermore, in TIA
patients The American-Canadian Co-Operative Study
Group (21) has demonstrated that after a mean follow-up
of 25 months there was no difference in mortality, stroke
or retinal infarction between patients randomised to
aspirin plus placebo or aspirin plus dipyridamole. There
are several explanations for this discrepancy between our
results and previous data. One explanation could be that
the present study was non-randomised in contrast to pre-
vious randomised trials, which means that our results must
be interpreted with extreme caution. In previous studies
[8,9,21] the mean follow-up was between 24 months and
3.5 years in comparison with 12-months follow-up in the
present study. During longer follow-up, risk factors for car-
diovascular mortality may be more impending and may
counteract the early positive effects of A + D.
The difference in mortality rate between A + D vs.
aspirin only users in the present study was solid in spite
of a smaller population sample and was demonstrated
early after stroke. It may be hypothesized, that time from
onset of stroke to initiation of antiplatelet therapy may
be important.
In the present study acute stroke patients were enrolled if
they had experienced a stroke/TIA within preceding 7 days.
In previous, randomised studies [8,9,21] patients were eli-
gible for inclusion in the non-acute setting i.e. the index
stroke must have occurred within 3 and, respectively, 6 pre-
ceding months. Thus, in the present study treatment with
antiplatelet was initiated very early and considering the sug-
gested neuroprotective effects of dipyridamole and the
antithrombotic properties of aspirin it may be hypothe-
sized, that these early effects may be important for the sig-
nificant reduction in all-cause mortality.
This association is further delineated by the clear dif-
ference in all-cause mortality between A + D vs. aspirin
only users in the present study in comparison with pre-
vious studies [8,9,21].
Our patients were older, than in previous studies
[8,9,21], which must be considered as a factor of potential
importance. Increasing age may substantially augment
mortality rate but in spite of this, the consistent effects onmortality persisted during the whole observational period.
Furthermore, patients treated with ActilyseW (Boehringer-
Ingelheim) were not included in the study. Only around
6.6% of all stroke patients were treated by ActilyseW during
this period in Sweden so, tentatively, inclusion of
ActilyseW treated patients would only have a marginal
effect on the present results [22].
There was no difference at discharge in systolic or dia-
stolic blood pressure nor in LDL-C, total cholesterol and
triglycerides. If anything, HDL-C was slightly lower in
the A + D group which, conversely, may suggest an
increased risk profile in A + D users, but the difference
was quite small. Therefore, it is not possible to discern a
higher risk profile in the aspirin only group.
In disparity with previous studies [8,9] there was no
difference in secondary stroke prevention in A + D users
vs. users of aspirin only. Conceivably, this finding may
depend on the low numbers of recurrent strokes during
follow-up.
There are several limitations of the present work. This
study was not randomised, but a post-hoc analysis of data
collected from a stroke registry study. Our findings, which
are in contradiction with results from several randomized
trials, should therefore be interpreted with great caution.
Our sample size was also much smaller than in previous
randomised studies [8,9,21]. Numerous factors may influ-
ence use of A + D or aspirin only and these factors may
be distributed dissimilarly among the two groups.
However, the influence of potential confounding fac-
tors such as age, stroke severity, previous stroke, previ-
ous myocardial infarction, and diabetes type 2, were
taken into account and adjusted for in the survival ana-
lysis. We cannot, however, completely rule out that there
are still some unknown factors that have substantially
influenced our findings.
For pre-stroke use of A + D or aspirin only informa-
tion was obtained from patients, next of kin or medical
records, but there may be a bias even if information was
meticulously collected. At discharge we recorded use of
drugs but we cannot confirm that all patients remained
on these drugs during follow-up.
The strength of the present study is that the popula-
tion is large and that most patients have been followed
for 12months.
Furthermore, all admitted stroke patients were
included in the present study and there were very few
patients lost to follow-up. However, our findings may
not be valid for a general stroke population, but merely
for a somewhat older stroke population, given the rather
high mean age of our study population.
Conclusions
In acute ischemic stroke/TIA pre-treatment with A + D
does not seem to lessen clinical stroke severity. Nevertheless
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one year after ischaemic stroke compared to aspirin only.
Based on these findings and considering the limita-
tions mentioned above, we cautiously suggest that early
initiation of these drugs in acute stroke may have an
important protective effect and may improve survival,
making the combination of A + D to be preferred to
aspirin only. We must, however, as previously mentioned,
be very cautious to draw any conclusion from the present
data considering the non-randomised study design.
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